Author profile
A. Jon Stoessl, MD, FRCPC
Introduction The introduction to the Canadian market of three new drugs for the management of Parkinson’s disease (PD) in the last 2 years (one of which has been withdrawn due to rare hepatic toxicity) has left... Read More